Evidence map›Paper›PMID 42220470›Full record

ArticleClinical, cosmetic and investigational dermatology2026

Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis.

Xinyi Lu, Yuqiao Zhang, Hanlin Zhang, Keyun Tang, Hongzhong Jin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinyi Lu *Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Yuqiao Zhang *Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Hanlin ZhangDepartment of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.ORCID 0000-0001-5065-4086
Keyun TangDepartment of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Hongzhong JinDepartment of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While bullous pemphigoid (BP) can be induced by various drugs, cases involving small-molecule inhibitors remain rare. We report the first case of BP occurring in a patient with psoriasis shortly after receiving deucravacitinib, a TYK2 inhibitor. Following treatment with methylprednisolone, minocycline, and ixekizumab, the lesions resolved within one month. Although the precise mechanism remains unclear, it may involve immunological drift and remodeling of skin immune microenvironment, which raises the need for clinical awareness regarding such reactions when using novel targeted immunomodulators.

Indexed as

bullous pemphigoiddeucravacitinibpsoriasisTYK2 inhibitor

Identifiers

PMID42220470
PMCPMC13222050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.